Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal experimental study without human clinical data.
PubMed 27847966 · doi:10.1007/s00109-016-1488-y
What was done
Researchers evaluated the pro-angiogenic properties and molecular mechanisms of the pentadecapeptide BPC 157 across three experimental systems: in vivo chick chorioallantoic membrane (CAM) assays, in vitro endothelial tube formation using human vascular endothelial cells, and a surgically induced hind limb ischemia model in rats. Blood flow recovery was tracked with laser Doppler scanning, tissue vessel density and vascular endothelial growth factor receptor 2 (VEGFR2) expression were examined histologically, and downstream signaling (including VEGF-A, VEGFR2 internalization, and VEGFR2-Akt-eNOS pathway activation) was assessed in vitro with and without the endocytosis inhibitor dynasore.
What was found
The abstract reports no numerical values, effect sizes, or statistical confidence intervals. Qualitatively, BPC 157 increased vessel density in CAM assays and stimulated endothelial tube formation in vitro. In ischemic rat hind limbs, BPC 157 treatment accelerated blood flow recovery, increased vessel numbers, and increased vascular VEGFR2 expression. In cultured human endothelial cells, BPC 157 upregulated VEGFR2 mRNA and protein levels without altering VEGF-A, and stimulated VEGFR2 internalization and time-dependent activation of the VEGFR2-Akt-eNOS pathway. Co-treatment with dynasore blocked VEGFR2 internalization, VEGFR2-Akt-eNOS signaling, and endothelial tube formation.
Why it matters
This study defines a specific downstream signaling pathway (VEGFR2 expression, endocytosis, and VEGFR2-Akt-eNOS activation) underlying BPC 157-mediated angiogenesis in preclinical models of tissue ischemia.
Limits
The study is entirely preclinical, relying on cell culture and animal models; results cannot be directly extrapolated to human clinical efficacy or safety. The abstract provides no quantitative data, sample sizes, dosage details, or statistical parameters, preventing independent verification of effect magnitudes.
Cited by
- supports BPC-157 promotes vascular endothelial growth factor (VEGF) signaling, stimulating angiogenesis and modulating nitric oxide synthesis in tissue injury models.